Quick Facts

• Condition Management: May be utilized to support management of gastrointestinal symptoms.
• Symptom Relief: A therapeutic option to address postprandial fullness, upper abdominal discomfort, and sensation of bloating.
• Primary Uses: Indicated for certain symptoms associated with chronic gastritis and functional dyspepsia.

---

Itomash (Itopride) is a therapeutic agent available to support the management of various upper gastrointestinal symptoms. It is a medication that may be considered for individuals experiencing chronic discomfort in the upper abdomen, including the frequent sensation of postprandial (after-meal) fullness or early satiety.

This medication is primarily used to address symptoms associated with conditions like chronic gastritis and functional dyspepsia, which are often characterized by reduced gastrointestinal (GI) motility. Potential benefits may include a positive effect on symptoms such as feelings of bloating, heartburn, loss of appetite, and episodes of nausea or vomiting. The use of this agent is intended to provide symptom relief and help manage the manifestations of these GI motility conditions.

For a comprehensive review of the approved therapeutic applications and clinical information, patients and caregivers should consult official guidance and product documentation.

Regulatory References

1. FDA Verification Portal

Who can and cannot use Itomash?

Itomash (Itopride) is indicated for use in adults who meet the specific regulatory criteria outlined in the prescribing information. Official regulatory documents define clear population-based exclusions and restrictions to guide appropriate use.

Absolute Contraindications

The medicine must not be used in patients with known hypersensitivity to Itopride hydrochloride or any of the product's components. It is strictly contraindicated in any condition where an increase in gastrointestinal motility could be detrimental, including gastrointestinal hemorrhage, mechanical obstruction, or perforation.

Restricted and Not Recommended Populations

• Pediatric Use: Use is not recommended in children under 16 years, as safety and effectiveness have not been established for this age group in official labeling.
• Pregnancy and Lactation: Use is generally not recommended for women who are pregnant or breastfeeding, as official human safety data is considered insufficient.
• Organ Function: Patients with reduced hepatic or renal function require administration with adequate caution and close monitoring. Dosage adjustments may be necessary for these populations, as specified in the official labeling.
• Older Adults: Use in this population also requires adequate caution due to the higher potential for reduced physiological functions.

Interactions with other medicines and products

Interaction Scope

Medicinal Product Categories
Anticholinergic drugs
Oral medicines with a narrow therapeutic index or specialized release (e.g., sustained-release or enteric-coated formulations)

Specific Interacting Medicines (Officially Documented Outcomes)

• Anticholinergic Agents (e.g., atropine): Co-administration may result in pharmacodynamic antagonism, which is a reduction in the prokinetic action of Itomash.
• Anti-ulcer Agents (e.g., Cimetidine, Ranitidine): Official regulatory documents confirm that these agents do not affect the prokinetic action of Itomash.
• Highly Protein-Bound Drugs (e.g., Warfarin, Diazepam): No changes in protein binding have been detected when co-administered with Itomash.

Metabolic and Absorption-Related Statements

• Metabolic Stability (FMO Pathway): Itomash is primarily metabolized by the Flavin-containing Monooxygenase (FMO) enzyme system and not the common Cytochrome P450 (CYP450) system, specifically CYP3A4. Accordingly, significant metabolic pharmacokinetic interactions are not expected with drugs that inhibit or induce CYP450 enzymes.
• Physiological Absorption Impact: The gastrokinetic effect of Itomash, which accelerates gastric emptying, has the potential to influence the absorption of other orally administered medicines.

Regulatory Constraints and Considerations

Regulatory Constraint	Description (As per Official Labeling)
Timing-based Rule	Particular caution is required with co-administration of oral drugs whose absorption may be significantly affected by accelerated gastric emptying.
Interaction-Related Restriction	Use is contraindicated in conditions where increased gastrointestinal motility could be harmful, such as gastrointestinal hemorrhage, mechanical obstruction, or perforation.

Connection to the overall interaction profile: The regulatory profile highlights a low expected risk for common CYP450-mediated pharmacokinetic interactions due to the drug's primary metabolism via FMO. The documented interaction risks are predominantly pharmacodynamic, involving antagonism with anticholinergic agents, and physiological, related to the potential impact of accelerated gastric emptying on the absorption of concurrently administered oral medicines.

Itomash, containing itopride, functions through a dual pharmacological mechanism. The primary biological targets are the D2 dopamine receptors and the enzyme acetylcholinesterase ( AChE).

Itopride acts as a selective antagonist at peripheral D2 dopamine receptors, predominantly in the enteric nervous system. Dopamine typically exerts an inhibitory influence on acetylcholine ( ACh) release from myenteric motor neurons. By blocking the D2 receptor, Itomash removes this inhibitory tone, leading to an increase in ACh concentrations at the synapse.

Concurrently, Itomash functions as an inhibitor of AChE, the enzyme responsible for the hydrolysis and inactivation of ACh. This inhibition further elevates the concentration of endogenous ACh within the gastrointestinal tract.

The net consequence of this dual action—enhanced ACh release and reduced ACh degradation—is augmented muscarinic stimulation of smooth muscle cells in the gastrointestinal wall. This intracellular cascade culminates in increased amplitude of smooth muscle contraction. At the system level, this physiological modulation is characterized by accelerated gastric emptying, stimulation of gastric motility, and increased pressure of the lower esophageal sphincter.

How Itomash is Used: Official Administration Guidelines

Itomash (Itopride hydrochloride) is an oral prokinetic agent administered according to a specific schedule to support its intended use in upper gastrointestinal motility management. The administration of this medicine is defined by guidance concerning dose, frequency, timing, and duration.

The standard approach involves taking the medicine as a 50 mg film-coated tablet three times a day. This pattern establishes the maximum total daily dose at 150 mg.

---

Administration Protocol

The primary principle for its use is the time-relationship with meals: the tablets must be taken before meals. The tablets must be swallowed whole with liquid, as they are not intended to be crushed or chewed for the purpose of dose division.

Usage Constraint	Official Requirement
Route of Administration	Oral
Standard Adult Frequency	Three times a day (TID)
Timing Relative to Food	Must be taken before meals
Max. Treatment Duration	Generally should not exceed eight weeks

---

Use in Specific Populations

Administration to older adults requires particular caution and careful monitoring due to the potential for age-related decline in liver or kidney function. For patients with known hepatic or renal impairment, monitoring is also necessary, and adjustments to the dose or discontinuation of therapy may be considered if adverse reactions occur. Use in pediatric patients under 16 years of age is not established in the official prescribing information.

Research evidence / Overview of studies for Itomash

Evidence for Use in Functional Dyspepsia (FD)

Research examined Itomash for symptoms related to functional dyspepsia (FD), a condition where symptoms may vary in intensity and are often linked to functional limitations in the digestive system. The main research relied on large, short-term clinical trials lasting approximately eight weeks. These trials were typically double-blind, placebo-controlled studies involving adult patients diagnosed using specific clinical criteria for FD. Studies monitored patient-reported outcomes describing perceived discomfort and changes in symptom severity.

When data from multiple trials were combined in systematic reviews and meta-analyses, studies report how symptoms evolved in the observed populations compared to placebo. Meta-analyses generally described a pattern where patient-reported outcomes describing perceived discomfort were monitored. Research highlights changes measured during the study period for postprandial fullness and early satiety, where the data presented less variability compared to other outcomes, such as pain. The long-term effects are not fully established, as high-quality, controlled research has not been conducted over extended periods.

Studies on Secondary Motility-Related Symptoms

Research has also explored the use of Itomash in other contexts, particularly for symptoms of delayed gastric emptying (gastroparesis). These investigations were generally small-scale, non-pivotal pilot controlled studies. Studies monitored functional outcomes, such as the rate at which the stomach empties its contents, as well as patient-reported outcomes describing perceived discomfort like nausea. Evidence is limited for these applications; the data available primarily reflects very short follow-up durations (e.g., 2 to 4 weeks).

Key Evidence Gaps and Research Uncertainty

A significant body of research examined Itomash; however, several limitations and gaps are acknowledged in the scientific literature. Follow-up durations were limited in the most rigorous, controlled settings, meaning long-term effects are not fully established. Additionally, evidence quality varies across studies, and data for certain groups remain insufficient because most large trials excluded specific populations, such as children under 16 years of age. Research does not determine whether an individual will respond similarly to the group patterns described in the studies.

Common questions about Itomash (FAQ)

---

Q: How long do I typically need to take Itomash?

A: Studies used to determine the effectiveness of Itomash often focus on short-term treatment durations. Official regulatory documents indicate that the use of this medication should generally not exceed a period of eight weeks.

Q: Does Itomash cause weight gain or weight loss?

A: According to official product information, changes in body weight, such as weight gain or weight loss, are not typically listed as a common or uncommon side effect of Itomash in the adverse reaction tables.

Q: What should I do if I miss a dose of Itomash?

A: Regulatory documents state that if a regular dose is missed, it should be taken as soon as it is remembered. However, if it is already close to the time for the next scheduled dose, the missed dose should be skipped. Product labels advise against taking two doses simultaneously and suggest simply resuming the regular dosing schedule.

Q: Can I drink alcohol while taking Itomash?

A: Official patient information often advises patients to avoid or minimize the consumption of alcohol while taking this medicine. This caution is in place because alcohol may potentially increase the risk of experiencing certain side effects.

Q: How long does it take for Itomash to start working?

A: Pharmacokinetic studies show that the medicine's concentration in the body reaches its maximum level, or peak, quite quickly after taking the tablet. This peak concentration is typically achieved about 30 to 45 minutes after oral administration.

How to Store and Dispose of Itomash?

The storage and disposal of Itomash (Itopride hydrochloride tablets) must align with the specific requirements documented in official regulatory labeling to ensure product stability and safe handling.

Official Storage Conditions

Itomash must be stored at or below 30 C and should be protected from light and moisture. The tablets must remain in their original primary packaging to maintain stability. The medicine must always be stored out of the sight and reach of children to prevent accidental ingestion.

Disposal Instructions

Unused or expired Itomash must be disposed of according to local regulatory requirements for pharmaceutical waste. The official labeling specifies that the product should not be disposed of via household wastewater or general trash.